Alpha Cognition to Present at LD Micro Main Event

Rhea-AI Summary

Alpha Cognition Inc. (TSX-V: ACOG)(OTCQB: ACOGF) is set to present at the LD Micro Main Event on October 12th at 3:00 PM EST in Los Angeles. CEO Michael McFadden will discuss the company's innovative therapies targeting neurodegenerative disorders, specifically highlighting ALPHA-1062 and ALPHA-0602. This annual event, running from October 12th to October 14th, features around 150 presenting companies and aims to connect investors with emerging opportunities.

Presentation on Tuesday, October 12^th at 3:00 PM EST

VANCOUVER, British Columbia--(BUSINESS WIRE)-- Alpha Cognition Inc. (TSX-V: ACOG)(OTCQB: ACOGF)(“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, is pleased to announce that it will be presenting at the 14th annual Main Event on Tuesday, October 12th at 3:00 PM EST at the Luxe Sunset Bel-Air in Los Angeles. Michael McFadden, CEO of Alpha Cognition, will provide an overview of the Company's business, highlighting the Company’s lead asset, ALPHA-1062, as well as its early stage asset, ALPHA-0602, during the presentation. The company will also host investor meetings after the presentation on Tuesday.

Event: LD Micro Main Event
Date: Tuesday, October 12th
Time: 3:00 PM EST

Register to watch the virtual presentation here.

Summary of LD Micro Main Event (XIV)

The 2021 LD Micro Main Event will be held at the Luxe Sunset Bel-Air in Los Angeles from Tuesday, October 12th to Thursday, October 14th.

The festivities run from 8 AM PT - 5:30 PM PT on the 12th and 13th with a morning session on the 14th.

This three-day, investor conference is expected to feature around 150 companies, presenting for 25 minutes each, as well as several influential keynotes in person.

For more info, please contact Dean@ldmicro.com

About Alpha Cognition Inc.

Alpha Cognition Inc. is a clinical stage, biopharmaceutical company dedicated to developing treatments for under-served neurodegenerative diseases, such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis (ALS).

ALPHA-1062, is a patented new chemical entity that has demonstrated safety and improved tolerability in human clinical trials. It is being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with minimal gastrointestinal side effects and novel routes of administration. ALPHA-1062's active metabolites are differentiated from donepezil and rivastigmine in that they may sensitize neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer's dementia and in a nasal spray formulation to treat traumatic brain injury.

ALPHA-0602 (Progranulin) is expressed in several cell types in the central nervous system and in peripheral tissues, regulates cell survival and certain inflammatory processes, and plays a major role in regulating lysosomal function and microglial responses to disease. Its use for the treatment of neurodegenerative diseases has been patented by the Company and granted an Orphan Drug Designation.

About LD Micro (NASDAQ: SRAX)

LD Micro aims to be the most crucial resource in the micro-cap world. Whether it is the index, comprehensive data, or hosting the most significant events on an annual basis, LD's sole mission is to serve as an invaluable asset for all those interested in finding the next generation of great companies.

http://www.ldmicro.com

Neither TSX Venture Exchange (the “TSX-V”), OTC Markets Group, nor the TSX-V’s Regulation Services Provider (as that term is defined in policies of the TSX-V) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking Statements

This news release is not, and under no circumstances is to be construed as, an advertisement or a public offering of securities. No securities commission or similar authority in Canada or in any other jurisdiction has reviewed or in any way passed upon this news release or the merits of the securities described herein and any representation to the contrary is an offence.

This news release includes forward-looking statements within the meaning of applicable securities laws. Except for statements of historical fact, any information contained in this news release may be a forward‐looking statement that reflects the Company’s current views about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Forward‐looking statements can be identified by the words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “contemplate,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward‐looking statements in this news release include statements regarding the Company’s business strategy, market size, potential growth opportunities, capital requirements, clinical development activities, the timing and results of clinical trials, regulatory submissions, potential regulatory approval and commercialization of the technology. Although the Company believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. The Company cannot assure that the actual results will be consistent with these forward-looking statements as a result of known and unknown risks, uncertainties, assumptions and other factors. These risks, uncertainties, assumptions and other factors include those associated with clinical studies and manufacturing, as well as development and commercialization of the Company’s products; the need for additional financing to maintain operations; risks posed by the economic and political environments in which the Company operates and intends to operate; market instability due to the COVID-19 pandemic; the potential for losses arising from the expansion of operations into new markets; increased competition; assumptions regarding market trends and the expected demand and desires for the Company’s products and proposed products; reliance on industry manufacturers, suppliers and key personnel; the failure to adequately protect intellectual property; a failure to adequately manage future growth; adverse market conditions; and failure to satisfy ongoing regulatory requirements or obtain regulatory approvals. These forward‐looking statements speak only as of the date of this news release and, other than as required by applicable securities laws, the Company undertakes no obligation to revise or update any forward‐looking statements, even if new information becomes available in the future.

This news release may also contain estimates and other statistical, market and industry data from independent parties or made by the Company relating to our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. We cannot guarantee the accuracy and completeness of information from third party sources.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211008005029/en/

Bristol Investor Relations

Stefan Eftychiou

905 326 1888 ext 6

stefan@bristolir.com

https://www.alphacognition.com/

Source: Alpha Cognition Inc.

FAQ

When is Alpha Cognition presenting at the LD Micro Main Event?

Alpha Cognition will present on October 12th at 3:00 PM EST.

What key products will Alpha Cognition discuss during the presentation?

Alpha Cognition will highlight ALPHA-1062 and ALPHA-0602.

Where is the LD Micro Main Event taking place?

The event will be held at the Luxe Sunset Bel-Air in Los Angeles.

What are the dates for the LD Micro Main Event?

The event runs from October 12th to October 14th.

How can investors watch Alpha Cognition's presentation?

Investors can register to watch the presentation virtually through a provided link.

What is the significance of ALPHA-1062 for Alzheimer's treatment?

ALPHA-1062 is a new acetylcholinesterase inhibitor with potential for minimal side effects and improved cognitive performance.

What does ALPHA-0602 target in neurodegenerative diseases?

ALPHA-0602 focuses on regulating cell survival and inflammatory processes in neurodegenerative diseases.

What is the role of SRAX in the LD Micro Main Event?

SRAX is the parent company of LD Micro, which organizes the annual investor conference.